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ABSTRACT
Background: The HIV/AIDS epidemic has been accompanied by a severe epidemic of tuberculosis (TB), although
the prevalence of coinfection is largely unknown, especially in developing countries, including Nigeria. The aim of
this study was to determine the prevalence and predictors of TB coinfection among HIV-seropositive Nigerians.
Methods: The case ﬁles of HIV/AIDS patients attending Aminu Kano Teaching Hospital, Nigeria from January to
December 2006 were reviewed.
Results: A total of 1320 HIV/AIDS patients had complete records and were reviewed, among which 138 (10.5%)
were coinfected with TB (95% CI, 8.9% to 12.2%). Pulmonary TB was diagnosed in 103 (74.6%) patients, among
whom only 18 (17.5%) were sputum-positive. Fifty (36.2%) coinfected patients had some type of extrapulmonary TB
(EPTB); 15 had both pulmonary TB and EPTB. Among the 35 patients with EPTB only, 20 (57.1%) had abdominal
TB, 5 (14.3%) had TB adenitis, 5 (14.3%) had spinal TB, 3 (8.6%) were being monitored for tuberculous meningitis,
and 1 (2.9%) each had renal TB and tuberculous adrenalitis. The highest prevalence of TB, 13.7% (n = 28), was seen
among patients aged 41–50 years. TB coinfection was signiﬁcantly associated with marital status, WHO clinical
stage, and CD4 count. Marital status (OR, 2.1; 95% CI, 1.28–3.59; P = 0.04), WHO clinical stage at presentation
(4.81; 1.42–8.34; P = 0.001), and baseline CD4 count (2.71; 1.51–6.21; P = 0.02) remained signiﬁcant predictors
after adjustment for confounding.
Conclusions: The moderately high prevalence of TB among HIV-seropositive patients underscores the urgent need
for strategies that lead to rapid identiﬁcation and treatment of coinfection with active or latent TB.
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INTRODUCTION
Worldwide, the HIV/AIDS epidemic has been accompanied
by a severe epidemic of tuberculosis (TB).1 The World
Health Organization (WHO) reported 8.8 million new cases of
TB and 1.6 million TB-related deaths in 2005, of which
195 000 were HIV-infected patients.2 HIV infection is the
leading risk factor for TB; HIV promotes progression of
latent or recent infections of Mycobacterium tuberculosis
to active disease, and also increases the rate of recurrence of
TB. People with HIV may also be more susceptibility to TB
infection.3
There have been several studies of the prevalence of
HIV in TB patients in different parts of Nigeria, with
prevalences of 6.1% in Jos,4 12.7% in Ife,5 19% in
Maiduguri,6 and 28.1% in Ibadan7; the national median is
17.0%.8 Elsewhere in Africa, higher prevalences of 33.2%,
43.6%, and 57.1% were reported in Chad,9 Tanzania,10 and
Ethiopia,11 respectively. However, reports on the prevalence
of TB in HIV-infected patients in Nigeria have been limited to
Ibadan and Ilorin, where the prevalence of active TB among
HIV/AIDS patients was reported to be 32.8%12 and 40%,13
respectively. There has been no such report from our center.
The objectives of the present study were to determine the
prevalence of TB in HIV-seropositive adults treated at the
Prof. S. S. Wali Virology Centre of the Aminu Kano Teaching
Hospital, in Kano, northern Nigeria and to identify the
factors that are associated with the development of TB. This
information may assist health managers and health care
providers in increasing vigilance and providing integrated
services that improve outcomes for people living with HIV/
AIDS.
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METHODS
Setting
Established in 1988, the Aminu Kano Teaching Hospital
began offering clinical services in 1994 at a temporary site in
the Murtala Mohammed Specialist Hospital, Kano and later
moved to its present, permanent site in 1997. Situated in
Kano, the largest commercial center of northern Nigeria,
with over 9 million people,14 this 500-bed hospital receives
patients from Kano, and from the neighboring states of
Jigawa, Katsina, Kaduna, Bauchi, and Zamfara. The majority
of patients are indigenous Hausa-Fulani, although the Ibo and
Yoruba ethnic groups are also well represented. Most patients
are farmers, traders, businessmen, or civil servants. Five days
a week, the hospital operates a multidisciplinary, specialist
clinic for HIV/AIDS patients, which is located at the Prof.
S. S. Wali Centre. Examinations and antiretroviral drugs are
provided at no charge to all patients. Similarly, a DOTS
(Directly Observed Treatment, Short-Course) clinic has been
established within the same complex; it provides free
antituberculosis treatment to all TB patients. The present
study population comprised HIV/AIDS patients attending the
Aminu Kano Teaching Hospital HIV/AIDS specialist clinic
from January to December 2006.
Study design
The study was a retrospective review of patients’ case ﬁles.
Data collection
We reviewed the medical records of all HIV-seropositive
patients who had attended the Prof. S.S. Wali Virology Centre
of Aminu Kano Teaching Hospital from January to December
2006. Ethical clearance was obtained from the Aminu Kano
Teaching Hospital institutional review board. At the study
center, HIV infection is diagnosed using a combination of the
ELISA test for HIV-1 and HIV-2 and the Western blot test. A
positive result on the ELISA test is conﬁrmed using the
Western blot test. The HIV testing protocol in our center has
been described elsewhere.15 The procedure is as follows: after
obtaining informed consent, 10mL of blood is collected from
the patient. The sample is centrifuged at 3000 rpm for 10
minutes. The resulting serum is ﬁrst screened for the presence
of HIV antibodies using the ELISA technique with
Genescreen (Sanoﬁ, Pasteur). All initially reactive samples
are retested with another ELISA test kit (Biorad, USA).
Serum samples that were positive on the second ELISA are
then conﬁrmed using the Western blot (Biotech, Ireland)
or Immunoconﬁrm (Organics, Israel) test. All patients are
provided with pretest and posttest counseling. HIV-
seropositive patients who attended the clinic at least once
and had received a diagnosis of pulmonary or extrapulmonary
TB during the initial evaluation or on subsequent visits were
included in this study. A diagnosis of TB coinfection was
made on the basis of the Ziehl-Neelsen staining technique of
sputum, imaging study, biopsy of tissue specimen, TB culture
studies, or a combination of these. Bacteriological analysis
was performed in all cases. Patients that were treated for TB
and declared cured before presentation were not included.
Data regarding TB/HIV coinfection were extracted from case
records.
A standardized form was used to collect information about
age, sex, marital status, educational status, and occupation.
Other variables included identiﬁcation of all pulmonary TB
cases diagnosed by Ziehl-Neelsen staining, TB culture studies,
and image studies and all extrapulmonary TB cases diagnosed
by tissue histology and/or cytology among HIV-seropositive
patients. In addition, baseline CD4 count and WHO clinical
stage at presentation were recorded. The time of diagnosis of
TB relative to antiretroviral treatment was also noted.
Data analysis
The data were cleaned, validated, and analyzed using EPI
Info version 6 software (CDC Atlanta, Georgia, USA).16
Quantitative variables were summarized using range,
mean, and standard deviation, or median and quartiles, as
appropriate. Categorical variables were tabulated using
frequencies and percentages. The Mann Whitney U test was
used to compare median CD4 counts, and the chi-square test
was used for testing the signiﬁcance of association between
categorical variables. A bivariate analysis was performed,
including the calculation of crude odds ratios (ORs).
Adherence to antiretroviral therapy (ART) was not analyzed
because only 5 patients developed TB/HIV infection during
such treatment; these cases were therefore excluded from the
model. All variables that were signiﬁcantly associated with
TB/HIV coinfection were included in a multivariate logistic
regression analysis in order to determine their independent
effects. Adjusted ORs and their respective 95% conﬁdence
intervals (CI) were also obtained. The level of signiﬁcance
was set at P < 0.05.
RESULTS
Sociodemographic characteristics
Of the 1456 patients seen at the Prof. S. S. Wali Virology
Centre during the 1-year period under review, the records of
1320 (90.7%) were available for review. Of the case ﬁles
reviewed, 724 (54.8%) of the patients were males and 596
(45.2%) were females, the female-to-male ratio was thus
1:1.2. Patient age ranged from 16 to 76 years, with a mean age
of 34.2 ± 7.2 years. The average age [± SD] of the male
and female patients was 36.0 ± 8.3 and 30.1 ± 5.2 years,
respectively. More than 72% of the patients were aged
between 21 and 40 years. The majority (74.6%) of patients
were Muslims, who mostly (66.8%) belonged to the Hausa-
Fulani ethnic groups. Three hundred and thirty-three patients
(25.2%) were employed privately or by the government; 676
(51.2%) were unemployed. The remaining 311 (23.6%) were
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self-employed and engaged in different types of work. A total
of 451 (34.2%) of the patients had a tertiary education,
285 (21.6%) had a secondary education, 185 (14.0%) had a
primary education, and 399 (30.2%) had no formal education.
A total of 884 (67.0%) were married, 92 (7.0%) were
widowed, 229 (17.3%) were single, and 115 (8.7%) were
divorced. Their sociodemographic characteristics are shown in
Table 1.
Clinical characteristics
At presentation, 389 (29.5%), 213 (16.1%), 275 (20.8%), and
443 (33.6%) of the patients were in WHO stage I, II, III, and
IV, respectively. The median baseline CD4 count was 242
lymphocytes/µL with lower and upper quartiles of 130 and
401 lymphocytes/µL, respectively. Approximately 37.2%
of the patients had fewer than 200 CD4 lymphocytes/µL,
50.0% had between 200 and 599, and 12.9% had 600 or more
lymphocytes/µL at baseline.
Prevalence and pattern of TB/HIV coinfection
Of the 1320 HIV-seropositive patients, 138 were coinfected
with TB: a period prevalence of 10.5% (95% CI,
8.9%–12.2%). Among these 138 patients, TB coinfection
had been diagnosed before commencement of ART in 133
(96.4%); it was diagnosed during ART in 5 (3.6%). Among
patients coinfected with TB/HIV, 103 (74.6%) had pulmonary
TB (PTB), among whom only 18 (17.5%) were sputum-
positive. The great majority, 85 (82.5%), were sputum-
negative. Fifty (36.2%) coinfected patients had some type of
extrapulmonary TB (EPTB); 15 had both PTB and EPTB.
Among those with EPTB only, 20 (57.1%) had abdominal
TB—deﬁned as infection of the peritoneum, or the hollow or
solid abdominal organs, with Mycobacterium tuberculosis, as
conﬁrmed by histologic examination of biopsy specimens or
culture—5 (14.3%) had TB adenitis, 5 (14.3%) spinal TB,
3 (8.6%) were being followed for tuberculous meningitis, and
1 (2.9%) each had renal TB and tuberculous adrenalitis, as
shown in Table 2. In addition, among the patients with EPTB,
12 had pleurisy and 3 had pericarditis.
By sex, 81 (11.2%) of the 724 males had TB, as compared
to 57 (9.6%) of the 596 females. This difference was not
statistically signiﬁcant (χ2 = 0.92, P = 0.34). With respect
to age, the highest prevalence of TB (13.7%, n = 28) was
observed among patients aged 41–50 years, followed by
those aged 31–40 years (11.8%, n = 61) and 51–60 years
(10.1%, n = 8), as shown in Table 3. This trend was not
statistically signiﬁcant (χ2trend = 3.62, P = 0.06). With respect
to educational attainment, the highest prevalence was
observed among patients with a primary education (12.4%,
n = 23), followed by those with a tertiary education (10.6%,
n = 48) and secondary education (9.8%, n = 28). The
prevalence of TB among patients without formal education
was 9.8% (n = 39). Education status was not signiﬁcantly
associated with TB coinfection. With respect to marital status,
widowed patients had the highest prevalence (17.4%, n = 20),
followed by married patients (10.5%, n = 93) and single
patients (7.9%, n = 18). Differences due to marital status
were statistically signiﬁcant (χ2 = 10.86, P = 0.01). HIV-
seropositive patients coinfected with TB had a median CD4
Table 1. Sociodemographic characteristics of patients
receiving antiretroviral treatment at Aminu Kano
Teaching Hospital, Kano, Nigeria (n = 1320)
Characteristic Males Females
Frequency
No. (%)
Age
≤20 40 (5.5) 23 (3.9) 63 (4.8)
21–30 310 (42.9) 134 (22.5) 444 (33.6)
31–40 199 (27.5) 316 (53.0) 515 (39.0)
41–50 108 (14.9) 96 (16.1) 204 (15.5)
51–60 58 (8.0) 21 (3.5) 79 (6.0)
>60 9 (1.2) 6 (1.0) 15 (1.1)
Total 724 (100.0) 596 (100.0) 1320 (100.0)
Marital status
Single 167 (23.1) 62 (10.4) 229 (17.3)
Married 478 (66.0) 406 (68.1) 884 (67.0)
Widowed 40 (5.5) 52 (8.7) 92 (7.0)
Divorced 39 (5.4) 76 (12.8) 115 (8.7)
Total 724 (100.0) 596 (100.0) 1320 (100.0)
Educational status
Non-formal 112 (15.5) 287 (48.2) 399 (30.2)
Primary 87 (12.0) 98 (16.4) 185 (14.0)
Secondary 159 (21.9) 126 (21.1) 285 (21.6)
Tertiary 366 (50.6) 85 (14.3) 451 (34.2)
Total 724 (100.0) 596 (100.0) 1320 (100.0)
Religion
Muslim 605 (83.6) 380 (63.8) 985 (74.6)
Christian 119 (16.4) 216 (36.2) 335 (25.4)
Total 724 (100.0) 596 (100.0) 1320 (100.0)
Ethnicity
Hausa 307 (42.4) 263 (44.1) 570 (43.2)
Fulani 163 (22.5) 149 (25.0) 312 (23.6)
Igbo 81 (11.2) 68 (11.4) 149 (11.3)
Yoruba 47 (6.5) 41 (6.9) 88 (6.7)
Others 126 (17.4) 75 (12.6) 201 (15.2)
Total 724 (100.0) 596 (100.0) 1320 (100.0)
Table 2. Tuberculosis presentation in TB/HIV coinfected
patients at Aminu Kano Teaching Hospital, Kano
TB Type Males Females
Total
No. (%)
PTB and/or EPTB 81 (58.7) 57 (41.3) 138 (100.0)
PTB
Sputum-positive 10 (15.9) 8 (20.0) 18 (17.5)
Sputum-negative 53 (84.1) 32 (80.0) 85 (82.5)
Total 63 (100.0) 40 (100.0) 103 (100.0)
EPTB
Abdominal TB 8 (44.4) 12 (70.6) 20 (57.1)
Spinal TB 4 (22.2) 1 (5.8) 5 (14.3)
TB adenitis 3 (16.6) 2 (11.8) 5 (14.3)
TB meningitis on follow-up 1 (5.6) 2 (11.8) 3 (8.6)
TB adrenalitis 1 (5.6) — 1 (2.9)
Renal TB 1 (5.6) — 1 (2.9)
Total 18 (100.0) 17 (100.0) 35 (100.0)
TB = Tuberculosis PTB = Pulmonary tuberculosis EPTB = Extrapul-
monary tuberculosis
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lymphocyte count of 184/µL, as compared to 260/µL for
those without coinfection. This difference was statistically
signiﬁcant (P < 0.05, Mann Whitney U test). With respect to
WHO clinical stage, the likelihood of TB coinfection
increased signiﬁcantly with a higher WHO HIV stage at
presentation (χ2trend = 54.1, P < 0.01). The prevalences of TB
coinfection in patients at WHO clinical stages III and IV were
18.5% and 15.6%, respectively.
Bivariate analysis of TB coinfection by sociodemographic
variables, baseline CD4 count, and WHO clinical stage at
presentation revealed that TB coinfection was signiﬁcantly
associated with marital status, WHO clinical stage, and CD4
count. These 3 factors remained signiﬁcant predictors of TB
coinfection after exclusion of patients who developed TB
coinfection while on ART treatment, and after adjusting for
confounding by using multivariate analysis. There was a
doubling of risk for TB coinfection among patients who were
widowed, as compared to single patients. There was also a
more than 4-fold likelihood of TB coinfection among patients
presenting with WHO stage IV disease, as compared to those
presenting with stage I disease. In addition, the risk of TB
coinfection among patients with a CD4 count lower than 200
lymphocytes/µL was more than double that that of patients
with a count higher than 600 lymphocytes/µL, as shown in
Table 4.
DISCUSSION
In the present study, 10.5% of the HIV-seropositive patients in
our center had TB. This is much lower than the 40% and
32.8% prevalences of active TB reported among HIV-
seropositive patients in the Nigerian cities of Ilorin13 and
Ibadan,12 respectively. However, the prevalence observed in
the present study is higher than that in the United Sates.20
Evidence from areas with high TB and HIV burdens17–19
indicates a high incidence of TB/HIV coinfection. The
differences observed between our center and other Nigerian
centers could be due to selection factors: the other studies
Table 3. TB/HIV coinfection among HIV-seropositive patients attending Aminu Kano Teaching Hospital, Kano, Nigeria
Frequency
No. (%)
Characteristic Coinfected Not Coinfected Total χ2 P value
Sex
Female 57 (9.6) 539 (90.4) 596 (100.0)
Male 81 (11.2) 643 (88.8) 724 (100.0)
Total 138 (10.5) 1182 (89.5) 1320 (100.0) 1.49 0.47
Age (yrs)
≤20 4 (6.3) 59 (93.7) 63 (100.0)
21–30 36 (8.1) 408 (91.9) 444 (100.0)
31–40 61 (11.8) 454 (88.2) 515 (100.0)
41–50 28 (13.7) 176 (86.3) 204 (100.0)
51–60 8 (10.1) 71 (89.9) 79 (100.0)
>60 1 (6.7) 14 (93.3) 15 (100.0)
Total 138 (10.5) 1182 (89.5) 1320 (100.0) 3.62* 0.06
Educational status
Non-formal 39 (9.8) 360 (90.2) 399 (100.0)
Primary 23 (12.4) 162 (87.6) 185 (100.0)
Secondary 28 (9.8) 257 (90.2) 285 (100.0)
Tertiary 48 (10.6) 403 (89.4) 451 (100.0)
Total 138 (10.5) 1182 (89.5) 1320 (100.0) 1.91 0.59
Marital status
Single 18 (7.9) 211 (92.1) 229 (100.0)
Married 93 (10.5) 791 (89.5) 884 (100.0)
Divorced 7 (7.6) 85 (92.4) 92 (100.0)
Widowed 20 (17.4) 95 (82.6) 115 (100.0)
Total 138 (10.5) 1182 (89.5) 1320 (100.0) 10.86 <0.01
WHO stage
I 8 (2.1) 381 (97.9) 389 (100.0)
II 10 (4.7) 203 (95.3) 213 (100.0)
III 51 (18.5) 224 (81.5) 275 (100.0)
IV 69 (15.6) 374 (84.4) 443 (100.0)
Total 138 (10.5) 1182 (89.5) 1320 (100.0) 54.1* <0.01
CD4 count
<200 68 (13.8) 423 (86.2) 491 (100.0)
200–399 37 (9.3) 359 (90.7) 396 (100.0)
400–599 25 (8.9) 238 (91.1) 263 (100.0)
≥600 8 (4.7) 162 (95.3) 170 (100.0)
Total 138 (10.5) 1182 (89.5) 1320 (100.0) 11.2* <0.01
*Chi-square test for trend
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were conducted before free antiretroviral drugs were provided
in government hospitals. Antiretroviral drugs became free of
charge in Nigeria in 2005, before which only those who could
afford therapy went to hospitals, sometimes as a last resort,
which would have resulted in a pooling of late-stage patients
at these hospitals.
As the most populous country in sub-Saharan Africa,
Nigeria has the highest number of TB cases of any country on
the continent, about 449 558 in 2006.21 This high burden from
TB has placed it among the top 5 of the WHO’s high-burden
TB countries. Unfortunately, DOTS is available to only 75
percent of the Nigerian population. Of even greater concern,
the 20% rate of detection of new TB cases under DOTS is one
of the lowest in sub-Saharan Africa.21 Therefore, the rising
prevalence of TB among HIV patients has implications for the
already overburdened health systems in resource-poor settings
such as ours. TB programs are often unable to manage the
high number of HIV-related TB cases and ensure completion
of TB therapy. Current government efforts to control both TB
and HIV/AIDS will need to be augmented dramatically in
order to avert a healthcare disaster. We believe that, with a
current adult coinfection rate of 9.6 percent,21 expansion of
the DOTS programs will allow for more rapid and thorough
identiﬁcation of persons with HIV/AIDS.
The fact that TB was diagnosed before commencement of
ART in nearly all (96.4%) of the patients with TB coinfection
indicates that more vigilance among physicians could increase
the detection rate, thereby allowing early treatment of TB,
which would improve outcomes among these patients. The
majority (74.6%) of the coinfected patients presented with
PTB; 85 (82.5%) were sputum-negative. This is similar to
reports from Ilorin (79%)13 and Ibadan (78.6%).17 Elsewhere
in Africa, however, Range and colleagues reported a higher
proportion (81.2%) of pulmonary TB among HIV-seropositive
patients in Tanzania.10 This disparity could reﬂect differences
in the seroprevalence of HIV between these populations. The
proportion of sputum-negative patients in the present study
was higher than the 53%6 reported among TB/HIV coinfected
patients in Maiduguri, Nigeria. The preponderance of such
cases among coinfected patients in our study could be due to
the lower rate of caseation necrosis, and the consequent lower
numbers of acid-fast bacilli in the airway.22 HIV may also
reduce the speciﬁcity of sputum microscopy by increasing the
proportion of patients with non-tuberculous mycobacteria.23
Currently no other diagnostic tool, including sputum culture,
is available that could be used affordably in resource-poor
settings, where the burden of disease is greatest. Two new
tests can identify M. tuberculosis ribosomal RNA (MTD,
Gen-Probe, San Diego, Calif.) or DNA (Amplicor, Roche
Molecular Systems, Branchburg, N.J.) in clinical specimens
within 24 hours, but these tests are not feasible in our
setting.24 A study conducted in Zimbabwe reported improved
yield after concentrating their specimens.25
The proportion of extrapulmonary cases seen in the present
study (25.4%) is higher than the 21.4% and 21% reported
in Ibadan7 and Ilorin,13 respectively. Among the extra-
pulmonary forms, abdominal TB was the most frequent,
which accords with data in the literature on populations with a
similar level of immunosuppression.26,27 The results of the
present study show that, after adjustment for other variables,
TB was more frequent among widows, patients presenting at
late stage (WHO clinical staging), and those with a lower
baseline CD4 count. The high prevalence of TB (22.6%)
among widows may be related to a loss of economic support
after the demise of a breadwinner, who probably died of
AIDS. The present study also shows that a high CD4 count
may decrease the chance of developing TB. In the medical
literature, there is no clear cutoff for CD4 count above which
the risk for TB development is diminished. However, there is
a clear inverse correlation between CD4 count and the risk of
opportunistic infections and death.28,29 Markowitz et al.30
identiﬁed 2 major risk factors for TB progression: (1) a
positive result on a protein puriﬁed derivative test at baseline
or during the study, which indicates the importance of the
degree of previous or current exposure to Mycobacterium
tuberculosis, and (2) a low CD4 count, which shows the role
of immunodepression in the development of active TB.
Although, in the present study, some WHO stage-I and -II
patients were coinfected with TB—which indicates that no
stage is immune to TB coinfection—a higher likelihood of TB
coinfection at advanced WHO stages of the disease was
clearly observed in our patients. In the present study, the
Table 4. Predictors of tuberculosis coinfection among
patients receiving antiretroviral treatment at Aminu
Kano Teaching Hospital, Kano, Nigeria
Characteristic
Crude Adjusted (95%CI)
P Value
OR OR
Sex
Male 1.19 (0.82–1.73) 1.03 (0.91–1.43) 0.12
Female Referent
Age (yrs)
≥30 Referent
31–40 1.57 (1.01–2.44) 1.26 (0.35–2.03) 0.48
41–50 1.86 (1.08–3.19) 1.23 (0.65–3.29) 0.28
>50 1.24 (0.54–2.77) 1.02 (0.31–3.01) 0.45
Marital status
Single Referent
Married 1.39 (0.79–2.42) 1.21 (0.34–2.16) 0.12
Divorced 0.93 (0.35–2.56) 0.97 (0.63–3.53) 0.43
Widowed 2.50 (1.19–5.14) 2.1 (1.28–3.59) 0.04
WHO stage
I Referent
II 2.5 (0.83– 6.63) 1.37 (0.59–4.75) 0.20
III 5.90 (4.85–25.20) 3.22 (1.67–7.20) 0.001
IV 7.40 (4.01–20.02) 4.81 (1.42–8.34) 0.001
CD4 count
<200 3.26 (1.47–7.49) 2.71 (1.51–6.21) 0.02
200–399 2.10 (1.59–4.97) 1.87 (1.53–5.27) 0.03
400–599 2.13 (1.61–5.27) 1.63 (1.03–4.36) 0.03
≥600 Referent
OR = Odds Ratio CI = Conﬁdence Interval
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highest prevalence (17.6%) of TB was seen among patients
aged 41–50 years, which differs from the bimodal distribution
observed in Ibadan, Nigeria,12 and the peak in individuals
aged 20–40 years noted in Jos,4 Nigeria. This disparity may
be due to differences in demographic characteristics and/or
HIV risk distribution among different age groups in these
locations.
This study had several limitations. First, this was a facility-
based study; centers such as ours commonly receive the most
severe, complicated cases, and the diagnostic difﬁculties are
therefore greater. This may be an example of the iceberg
phenomenon, ie, the prevalence observed in the present study
may not accurately reﬂect that of the region as a whole.
Secondly, the DOTS center at our facility became operational
only in early 2007; therefore, some earlier cases may
have been referred to the Infectious Diseases Hospital for
supervision of DOTS therapy, which may have led to an
underestimation of prevalence. Finally, because of the study
design, the predictors of TB/HIV coinfection identiﬁed in the
present study may not be exhaustive. A known drawback of
retrospective reviews of case records is that the number of
variables available for examining predictors of disease is
limited. A prospective study is therefore recommended to
explore other factors that may be associated with TB/HIV
coinfection in this study population.
The moderately high rate of TB coinfection among patients
at our center underscores the importance of informing health
practitioners of the challenges of managing these patients,
beyond simply treating the individual diseases. Control of
both TB and HIV is likely to be most successful if programs
collaborate whenever possible and are closely integrated with
other healthcare providers. We therefore need to intensify our
search for TB in HIV-seropositive patients who attend HIV
service outlets and to provide isoniazid prophylaxis to
individuals with known or suspected latent infection with
Mycobacterium tuberculosis, in order to prevent progression
to active disease after exclusion of active TB. There is a need
to institute TB control measures both in healthcare settings
and in places where people with TB and HIV frequently
congregate. Measures should include early recognition,
diagnosis, and treatment of TB suspects, particularly those
with pulmonary TB; separation of pulmonary TB suspects
until a diagnosis is conﬁrmed or excluded; and maximization
of natural ventilation to protect HIV-seropositive individuals
from possible exposure to TB.
ACKNOWLEDEGMENT
The research was funded privately by the authors, who
are lecturers at Bayero University in Kano, Nigeria and
consultants to the Aminu Kano Teaching Hospital in Kano.
The ﬁrst author (Iliyasu Z) is a community physician and focal
person for the monitoring and evaluation of the President’s
Emergency Plan for AIDS Relief project. The second author
(Babashani M) is a chest physician and project coordinator for
the same project.
REFERENCES
1. World Health Organization (WHO). Frequently Asked Questions
About TB and HIV. Online at www.who.int/tb/hiv/faq.
(Accessed 14 July 2007).
2. Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack
C, Gandhi N, et al. Utility of Tuberculosis Directly Observed
Therapy Programs as Sites for Access to and Provision of
Antiretroviral Therapy in Resource-Limited Countries. Clin
Infect Dis. 2004;38 Suppl. 5:S421–8.
3. Stop TB Partnership. Talking Points-TB/HIV-June 2007.
Online at www.stoptb.org/wg/tb_hiv/assets/documents/
tbhivtalkingpoints.pdf (Accessed 14th July 2007).
4. Anteyi EA, Idoko JA, Ukoli CO, Bello CS. Clinical pattern of
human immunodeﬁciency virus infection (HIV) in pulmonary
tuberculosis patients in Jos, Nigeria. Afr J Med Med Sci. 1996
Dec;25(4):317–21.
5. Onipede AO, Idigbe O, Ako-Nai AK, Omojola O, Oyelese AO,
Aboderin AO, et al. Sero-prevalence of HIV antibodies in
tuberculosis patients in Ile-Ife, Nigeria. East Afr Med J. 1999
Mar;76(3):127–32.
6. Moses AE, Adelowo KA, Ajayi BB. Prevalence of HIV-1
infection among patients with leprosy and pulmonary
tuberculosis in a semi-arid region, Nigeria. J R Soc Health.
2003 Jun;123(2):117–9.
7. Ige OM, Sogaolu OM, Ogunlade OA. Pattern of presentation of
tuberculosis and the hospital prevalence of tuberculosis and
HIVco-infection in University College Hospital, Ibadan: a
review of ﬁve years (1998–2002). Afr J Med Med Sci. 2005
Dec;34(4):329–33.
8. Odaibo GN, Gboun MF, Ekanem EE, Gwarzo SN, Saliu I,
Egbewunmi SA, et al. HIV infection among patients with
pulmonary tuberculosis in Nigeria. Afr J Med Med Sci. 2006
Dec;35 Suppl:93–8.
9. Tosi CH, Ngamgro MN, Djimadoum N, Richard V, Ngangro
MN, Djimadoum N, et al. Study of HIV seroprevalence in
patients with pulmonary tuberculosis in 1999 in Chad. Med Trop
(Mars). 2002;62(6):627–33.
10. Range N, Magnussen P, Mugomela A, Malenganisho W,
Changalucha J, Temu MM, et al. HIV and parasitic co-
infections in tuberculosis patients: a cross-sectional study
in Mwanza, Tanzania. Ann Trop Med Parasitol. 2007
Jun;101(4):343–51.
11. Bruchfeld J, Aderaye G, Palme IB, Bjorvatn B, Britton S, Feleke
Y, et al. Evaluation of outpatients with suspected pulmonary
tuberculosis in a high HIV prevalence setting in Ethiopia:
clinical, diagnostic and epidemiological characteristics. Scand J
Infect Dis. 2002;34(5):331–7.
12. Awoyemi OB, Ige OM, Onadeko BO. Prevalence of active
pulmonary tuberculosis in human immunodeﬁciency virus
seropositive adult patients in University College Hospital,
Ibadan, Nigeria. Afr J Med Med Sci. 2002 Dec;31(4):329–32.
13. Salami AK, Katibi IA. Human immunodeﬁciency virus-
associated tuberculosis: pattern and trend in the University
of Ilorin Teaching Hospital. Afr J Med Med Sci. 2006
Tuberculosis and HIV Co-Infection among Nigerians86
J Epidemiol 2009;19(2):81-87
Dec;35(4):457–60.
14. National Population Commission. National Census 2006
Provisional ﬁgures, Federal Republic of Nigeria, 2007.
15. Nwokedi EE, Azeez-Akande O. The trend of HIV infection in
Kano, Nigeria-A seven year study of adult attendees of Aminu
Kano Teaching Hospital. Niger J Med. 2007;16(4):344–7.
16. Dean AG, Burton AH, Dicker RC. Epi Info Version 6. A word
processing, database and statistics program for epidemiology on
microcomputers,USD Inc., Stone Mountain, GA; 1999.
17. Mocroft A, Youle M, Phillips AN, Halai R, Easterbrook P,
Johnson MA, et al. The incidence of AIDS-deﬁning
illnesses in 4883 patients with human immunodeﬁciency
virus infection:Royal Free/Chelsea and Westminster Hospitals
Collaborative Group. Arch Intern Med. 1998;158:491–7.
18. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann
KA, Letvin NL, et al. Focal mycobacterial lymphadenitis
following initiation of protease-inhibitor therapy in patients
with advanced HIV-1 disease. Lancet. 1998;351:252–5.
19. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm
EB. Changing incidence of AIDS-deﬁning illnesses in the era of
antiretroviral combination therapy. AIDS. 1997;11:1731–8.
20. Albalak R, O’Brien RJ, Steve Kammerer J, O’Brien SM,
Marks SM, Castro KG, et al. Trends in Tuberculosis/Human
Immuodeﬁciency Virus Comorbidity, United States, 1993–2004.
Arch Intern Med. 2007;167(22):2443–52.
21. Global tuberculosis control: surveillance, planning, ﬁnance:
WHO report 2008. WHO/HTM/TB/2008.393.
22. American Thoracic Society. Diagnostic standards and
classiﬁcation of tuberculosis in adults and children. Am J
Respir Crit Care Med. 2000;161:1376–95.
23. Murcia-Aranguren MI, Gómez-Marin JE, Alvarado FS, Bustillo
JG, de Mendivelson E, Gómez B, et al. Frequency of tuberculous
and non-tuberculous mycobacteria in HIV infected patients from
Bogota, Colombia. BMC Infect Dis. 2001;1:21.
24. Havlir DV, Barnes PF. Tuberculosis in patients with
human immunodeﬁciency virus infection. N Engl J Med.
1999;340(5):367–73.
25. Apers L, Wijarajah C, Mutsvangwa J, Chigara N, Mason P,
van der Stuvft P. Accuracy of routine diagnosis of pulmonary
tuberculosis in an area of high HIV prevalence. Int J Tuberc
Lung Dis. 2004 Aug;8(8):945–51.
26. Barnes PF, Modlin RL. Human cellular immune responses to
Mycobacterium tuberculosis. Curr Top Microbiol Immunol.
1996;215:197–219.
27. Dube MP, Holtom PD, Larsen RA. Tuberculosis meningitis
in patients with and without human immunodeﬁciency virus
infection. Am J Med. 1992;93:520–4.
28. Barnes PF, Barrows SA. Tuberculosis in the 1990s. Ann Intern
Med. 1993;119(5):400–10.
29. Nunn AJ, Mulder DW, Kamali A, Ruberantwari A, Kengeya-
Kayondo J, Whitworth J. Mortality associated with HIV-1
infection over ﬁve years in a rural Ugandan population: cohort
study. BMJ. 1997;315:767–71.
30. Markowitz N, Hansen NI, Hopewell PC, Glassroth J, Kyale PA,
Mangura PT, et al. Incidence of Tuberculosis in the United
States among HIV-Infected Persons. Ann Intern Med.
1997;126(2):123–32.
Iliyasu Z, et al. 87
J Epidemiol 2009;19(2):81-87
